NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0049 | -6.125 | 0.08 | 0.0828 | 0.07 | 1059610 | 0.07395992 | DE |
4 | 0.0013 | 1.76151761518 | 0.0738 | 0.0828 | 0.07 | 444182 | 0.07415015 | DE |
12 | -0.0597 | -44.2878338279 | 0.1348 | 0.1702 | 0.0611 | 600024 | 0.09091422 | DE |
26 | -0.0727 | -49.1880920162 | 0.1478 | 0.18 | 0.0611 | 531888 | 0.11904925 | DE |
52 | -0.1599 | -68.0425531915 | 0.235 | 0.436 | 0.0611 | 684605 | 0.21681748 | DE |
156 | 0.0333 | 79.6650717703 | 0.0418 | 5.98 | 0.0398 | 349267 | 0.31226852 | DE |
260 | 0.0333 | 79.6650717703 | 0.0418 | 5.98 | 0.0398 | 349267 | 0.31226852 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.